ATE295740T1 - Modifizierte methioninase, deren verwendung, rekombinante wirtszellen die grosse mengen von methioninase produzieren und verfahren zur aufreinigung von methioninase - Google Patents

Modifizierte methioninase, deren verwendung, rekombinante wirtszellen die grosse mengen von methioninase produzieren und verfahren zur aufreinigung von methioninase

Info

Publication number
ATE295740T1
ATE295740T1 AT96921484T AT96921484T ATE295740T1 AT E295740 T1 ATE295740 T1 AT E295740T1 AT 96921484 T AT96921484 T AT 96921484T AT 96921484 T AT96921484 T AT 96921484T AT E295740 T1 ATE295740 T1 AT E295740T1
Authority
AT
Austria
Prior art keywords
methioninase
nucleic acid
further provides
invention further
encoding nucleic
Prior art date
Application number
AT96921484T
Other languages
English (en)
Inventor
Yuying Tan
Valeryi Lishko
Original Assignee
Anticancer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,519 external-priority patent/US5715835A/en
Application filed by Anticancer Inc filed Critical Anticancer Inc
Application granted granted Critical
Publication of ATE295740T1 publication Critical patent/ATE295740T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96921484T 1995-06-07 1996-06-07 Modifizierte methioninase, deren verwendung, rekombinante wirtszellen die grosse mengen von methioninase produzieren und verfahren zur aufreinigung von methioninase ATE295740T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/486,519 US5715835A (en) 1992-11-19 1995-06-07 Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions
US08/642,541 US5891704A (en) 1992-11-19 1996-05-03 Method to produce high levels of methioninase
PCT/US1996/009935 WO1996040284A1 (en) 1995-06-07 1996-06-07 Use of methioninase in anti-methionine and anti-homocysteine chemotherapy

Publications (1)

Publication Number Publication Date
ATE295740T1 true ATE295740T1 (de) 2005-06-15

Family

ID=27048715

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921484T ATE295740T1 (de) 1995-06-07 1996-06-07 Modifizierte methioninase, deren verwendung, rekombinante wirtszellen die grosse mengen von methioninase produzieren und verfahren zur aufreinigung von methioninase

Country Status (9)

Country Link
US (3) US5891704A (de)
EP (1) EP0839055B1 (de)
JP (2) JP2002531050A (de)
CN (1) CN1173745C (de)
AT (1) ATE295740T1 (de)
AU (1) AU708361B2 (de)
CA (1) CA2221690C (de)
DE (1) DE69634751T2 (de)
WO (1) WO1996040284A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461851B1 (en) 1992-11-19 2002-10-08 Anticancer, Inc. High expression modules containing two or more tandem copies of a methioninase encoding sequence
US5891704A (en) 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
CN1879890A (zh) * 1995-06-07 2006-12-20 抗癌公司 蛋氨酸酶在抗蛋氨酸和抗高半胱氨酸的化学治疗中的应用
WO1998040476A1 (fr) * 1997-03-13 1998-09-17 Shionogi & Co., Ltd. PROCEDE DE PRODUCTION DE CRISTAUX DE L-METHIONINE η-LYASE
EP1003848A2 (de) * 1997-05-30 2000-05-31 Anticancer, Inc. Verfahren zur aktivierung von inaktive gene und verfahren zur änderung der entwicklungsverhältnisse von zellen, geweben und organismen
US6468762B1 (en) 1997-07-24 2002-10-22 Anticancer, Inc. High specificity homocysteinases
DE69837205T2 (de) * 1997-08-08 2007-11-22 Anticancer Inc., San Diego Hochexprimierende module mit zwei oder mehreren tandemkopien einer für methioninase kodierenden sequenz
US6524571B1 (en) * 1998-10-16 2003-02-25 Anticancer, Inc. Methioninase gene therapy for tumor treatment
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US7192729B2 (en) 1999-07-06 2007-03-20 General Atomics Methods for assaying homocysteine
US6376210B1 (en) 1999-07-06 2002-04-23 General Atomics Methods and compositions for assaying analytes
JP2001123956A (ja) * 1999-10-25 2001-05-08 Toyota Autom Loom Works Ltd 可変容量型圧縮機における吸入弁構造
US6818752B2 (en) * 2000-01-31 2004-11-16 Biocatalytics, Inc. Synthetic genes for enhanced expression
US6366860B1 (en) 2000-01-31 2002-04-02 Biocatalytics, Inc. Synthetic genes for enhanced expression
WO2002020807A1 (fr) * 2000-09-05 2002-03-14 Shionogi & Co., Ltd. L-methionine $g(g)-lyase a fonction modifiee
IL138529A0 (en) * 2000-09-18 2003-09-17 Yeda Res & Dev High level expression of heterologous proteins
CA2435387A1 (en) * 2001-01-23 2002-08-01 Dusan Ninkov Pesticidal compounds and compositions
US7309486B1 (en) * 2002-11-15 2007-12-18 Mark Zamoyski HER cancer protocols
JP2004231585A (ja) * 2002-12-05 2004-08-19 Fancl Corp 生体内ホモシステインレベル低減用および上昇抑制用組成物
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
US20070207158A1 (en) * 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
US7264819B2 (en) * 2003-06-23 2007-09-04 Anticancer, Inc. Lyase treatment for P. carinii
EP1664326A2 (de) * 2003-07-31 2006-06-07 Anticancer, Inc. Verwendung von plp mit peg-rmetase in vivo für verbesserte wirksamkeit
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
EP2721057B1 (de) * 2011-06-15 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptide von brevibacterium aurantiacum und deren verwendung für die behanldung von krebs
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
CN105983103B (zh) * 2015-03-17 2025-01-07 广州华津医药科技有限公司 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用
CN104928310B (zh) * 2015-06-09 2018-05-11 湖北工业大学 甲硫氨酸裂解酶及其编码基因和生物合成方法
EP3187190A1 (de) * 2015-12-31 2017-07-05 Erytech Pharma Verfahren zur behandlung eines säugetiers, einschliesslich eines menschen, gegen krebs mittels methionin- und asparagindepletion
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
JP7176921B2 (ja) * 2017-10-19 2022-11-22 アンチキャンサー インコーポレーテッド 癌治療、予防及びアンチエイジングのための組み換えメチオニナーゼを含む製剤
CN108486074A (zh) * 2018-04-03 2018-09-04 西北工业大学 一种利用结晶法分离提纯超氧化物歧化酶的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298590A (en) * 1975-02-25 1981-11-03 Samuel Bogoch Detection of malignant tumor cells
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
JP2557053B2 (ja) * 1984-12-21 1996-11-27 バイオジェン インコーポレイテッド 腫瘍壊死因子の精製、製造および使用法
JPH0797997B2 (ja) * 1988-04-28 1995-10-25 帝人株式会社 新規生理活性ポリペプチド
US5891704A (en) 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
ES2184756T3 (es) * 1992-11-19 2003-04-16 Anticancer Inc Uso de metioninasa como agente antitumoral en quimioterapia antimetionina.
US5571510A (en) * 1993-12-29 1996-11-05 The Regents Of The University Of California Method for selective methionine starvation of malignant cells in mammals

Also Published As

Publication number Publication date
EP0839055B1 (de) 2005-05-18
US5888506A (en) 1999-03-30
JP2002531050A (ja) 2002-09-17
US6231854B1 (en) 2001-05-15
CA2221690A1 (en) 1996-12-19
AU708361B2 (en) 1999-08-05
EP0839055A1 (de) 1998-05-06
AU6270196A (en) 1996-12-30
WO1996040284A1 (en) 1996-12-19
CA2221690C (en) 2013-11-26
EP0839055A4 (de) 2002-01-02
CN1173745C (zh) 2004-11-03
DE69634751D1 (de) 2005-06-23
CN1174512A (zh) 1998-02-25
DE69634751T2 (de) 2006-02-23
US5891704A (en) 1999-04-06
JP2004081209A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
DE69634751D1 (de) MODIFIZIERTE METHIONINASE, DEREN VERWENDUNG, REKOMBINANTE WIRTsZELLEN DIE GROSSE MENGEN VON METHIONINASE PRODUZIEREN UND VERFAHREN ZUR AUFREINIGUNG VON METHIONINASE
BR9306689A (pt) Sequência de dna purificada isolada gene híbrido específico de polén processo para conferir expressão específica de polén para gene em polén e polén transformado
DE69837041D1 (de) Verfahren und mikroorganism zur herstellung von purin-nukleosiden durch fermentation
DE69720473D1 (de) Verfahren zur reinigung von nukleinsäuren
DE60029195D1 (de) Verfahren zur gewinnung von purifizierter virenzuammensetzung
DE69634043D1 (de) Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie
ATE414162T1 (de) Verfahren und materialien zur herstellung von glucosamin
DE69434166D1 (de) Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen
AU2489197A (en) Carbocyclic intermediates and process of manufacture thereof
BR9607300A (pt) Polinucleotídeo transcrito de rna cdna vetor de dna biologicamente funcional célula hospedeira processo para produzir um polipeptídeo polipeptídeo produto de anticorpo hibridoma e linhagem de célula de hibridoma
ATE420192T1 (de) Verfahren zur verringerung der antigenität des adeno-assoziierten virus strukturproteins
BR9407874A (pt) Proteína purificada de mamiferos designada por mitosina fragmento biologicamente ativo proteina purificada de mamiferos molécula isolada de ácido nucléico vetor de expressao sistema de vetor-hospedeiro para produçao de mitosina anticorpo antimitosina e processo para produçao de mitosina
ATE207859T1 (de) Verfahren zur herstellung von pentafluorethan
Havron et al. Specificity of photochemical crosslinking in protein-nucleic acid complexes: identification of the interacting residues in RNase-pyrimidine nucleotide complex
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
BR0011033A (pt) Métodos de purificação de dna e dna purificado
DE59611206D1 (de) Thermolabile uracil-dna-glykosylase, verfahren zu deren herstellung und verwendung zur entfernung von uracil aus dna
Wu et al. Base-Pairing Systems Related to TNA: α-Threofuranosyl Oligonucleotides Containing Phosphoramidate Linkages1
BR9510089A (pt) Processo para a purificação de dna duplo-filamento composição farmacêutica e preparação de dna plasmídico recombinante purificado
ATE308619T1 (de) Steigerung der genexpression
DE59608651D1 (de) Verfahren zur sequenzierung durch oligomerhybridisierung
EP0642507A4 (en) Catalytic antibodies against cocaine and methods of using and producing same.
ATE203271T1 (de) Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung
BR9606440A (pt) Processo para classificar neuropatologia dna isolado e purificado polinucleotídeo quimérico vetor de expressão e célula hospedeira
Goldfarb et al. In vitro transcription and isolation of a polycistronic RNA product of the T4 tRNA operon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties